Patients were randomized 1:1 to receive QW exenatide 2 mg or pla- cebo injection in addition to their existing IG /C6metformin regimen. Randomization was performed centrally via an interactive web sys-tem and stratified by screening HbA1c of <9.0% or ≥9.0% (<75 or ≥75 mmol/mol) and prior sulphonylurea use. To ensure blinding, patients, investigators, study-site personnel and sponsor personnel did not have access to treatment codes or central laboratory FPG or HbA1c results for post-randomization visits. 2.3 |Procedures Before administration of study drugs, patients (or caregivers) were instructed on product reconstitution and administration. Exenatide